Cited by 280Cancer survivorship and careOvarian cancer diagnosis and treatmentChildhood Cancer Survivors' Quality of Life

The DOI matches its Crossref record; 27 of the 28 references it cites were found in a registry or an index.

Reliability and validity of the functional assessment of cancer therapy-ovarian

Basen-Engquist, Karen, Bodurka-Bevers, Diane, Fitzgerald, Mary A., Webster, Kimberly, Cella, David, Hu, Shaohua, Gershenson, David M.·2001·Journal of Clinical Oncology

DOI 10.1200/jco.2001.19.6.1809

Open this paper in CoChat — free account

Abstract

PURPOSE: To report the reliability and validity of the Functional Assessment of Cancer Therapy-Ovarian (FACT-O) in a consecutive series of outpatients with epithelial ovarian cancer. PATIENTS AND METHODS: Two hundred thirty-two ovarian cancer patients attending an outpatient gynecologic oncology clinic completed questionnaires at baseline. The patients' FACT-O scores were compared with their performance status, disease stage, treatment status, and other factors hypothesized to be related to quality of life. Patients received a second questionnaire either one week after baseline to assess the instrument's test-retest reliability and/or two months after baseline to evaluate its sensitivity to change in performance status. RESULTS: Internal consistency and test-retest reliability of the FACT-O were adequate. Overall, the scales correlated with other measures as expected; all correlations were in the hypothesized direction. Patients with advanced disease, poor performance status, and who were receiving active treatment had lower scores on physical, functional, and ovarian cancer-specific scales. The total FACT-O and emotional well-being scores were lower for patients with poor performance status and patients in active treatment. The FACT-O total and all subscale scores except emotional well-being were sensitive to decreases in performance status. CONCLUSION: Overall, the FACT-O provides a reliable and valid assessment of the quality of life of women with ovarian cancer, and is appropriate as a brief quality of life assessment in clinical trials and descriptive studies.

Integrity signals

Registry

Crossref · 10.1200/jco.2001.19.6.1809

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The CES-D Scale: A Self-Report Depression Scale for Research in the General Population
Radloff, L. S. (1977) · Applied Psychological Measurement · doi:10.1177/014662167700100306 · Cited by 53,267
Applied Multivariate Statistics for the Social Sciences
Stevens, J. P. (2012) · Routledge eBooks · doi:10.4324/9780203843130 · Cited by 10,652
A new scale of social desirability independent of psychopathology.
Crowne, D. P., & Marlowe, D. (1960) · Journal of Consulting Psychology · doi:10.1037/h0047358 · Cited by 8,686
The functional assessment of cancer therapy scale: development and validation of the general measure
Cella, D. F., Tulsky, D. S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., Silberman, M., Yellen, S. B., Winicour, P., & Brannon, J. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.3.570 · Cited by 6,020
Self-citation
Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system.
Yellen, S. B., Cella, D. F., Webster, K., Blendowski, C., & Kaplan, E. (1997) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(96)00274-6 · Cited by 1,964
Self-citation
Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument.
Brady, M. J., Cella, D. F., Mo, F., Bonomi, A. E., Tulsky, D. S., Lloyd, S. R., Deasy, S., Cobleigh, M., & Shiomoto, G. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.974 · Cited by 1,752
Self-citation
The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress
Portenoy, R. K., Thaler, H. T., Kornblith, A. B., Lepore, J. M., Friedlander-Klar, H., Kiyasu, E., Sobel, K., Coyle, N., Kemeny, N. E., Norton, L., et al. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)90182-1 · Cited by 1,580
Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation.
Schipper, H., Clinch, J., McMurray, A., & Levitt, M. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.5.472 · Cited by 1,052
Appraisal of methods for the study of chemotherapy of cancer in man: Comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide
Zubrod, C. G., Schneiderman, M. A., Frei, E., Brindley, C. O., Gold, G. L., Shnider, B. I., Oviedo, R., Gorman, J. G., Jones, R., Jonsson, U., et al. (1960) · Journal of Chronic Diseases · doi:10.1016/0021-9681(60)90137-5 · Cited by 1,034
Reliability and validity of the functional assessment of cancer therapy—lung (FACT-L) quality of life instrument
Cella, D. F., Bonomi, A. E., Lloyd, S. R., Tulsky, D. S., Kaplan, E. J., & Bonomi, P. (1995) · Lung Cancer · doi:10.1016/0169-5002(95)00450-f · Cited by 750
Self-citation

Flagged first, then by citations

Show all 28 references

1 of the 28 references couldn’t be matched to a known paper.

Sorted by citations

Items 101–200 of 277

Phase I/II study of weekly paclitaxel plus carboplatin and gemcitabine as first-line treatment of advanced-stage ovarian cancer: Pathologic complete response and longitudinal assessment of impact on cognitive functioning
Hensley, M. L., Correa, D. D., Thaler, H. T., Wilton, A. S., Venkatraman, E. S., Sabbatini, P. J., Dennis, S., Dupont, J., Spriggs, D. R., & Aghajanian, C. A. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.12.042 · Cited by 32
The use of patient-reported outcome tools in Gynecologic Oncology research, clinical practice, and value-based care
Moss, H. A., & Havrilesky, L. J. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.11.011 · Cited by 32
Quality-of-Life Outcomes in Oncology
Siddiqui, F., Kachnic, L. A., & Movsas, B. (2006) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2006.01.003 · Cited by 31
Quality of life evaluations in patients with ovarian cancer during chemotherapy treatment
Le, T. V., Leis, A. M., Pahwa, P., Wright, K., Ali, K., Reeder, B. A., Hopkins, L., & Fung, M. F. K. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2003.11.034 · Cited by 31
Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: An ancillary data analysis of the NRG Oncology/Gynecologic Oncology Group (GOG-0218) study
Phippen, N. T., Secord, A. A., Wolf, S. P., Samsa, G. P., Davidson, B. A., Abernethy, A. P., Cella, D. F., Havrilesky, L. J., Burger, R. A., Monk, B. J., et al. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.07.121 · Cited by 30
Self-citation
Assessment and Significance of Quality of Life in Women with Gynecologic Cancer
Chase, D. M., Watanabe, T., & Monk, B. J. (2010) · Future Oncology · doi:10.2217/fon.10.96 · Cited by 30
Obesity is associated with worse quality of life in women with gynecologic malignancies: An opportunity to improve patient‐centered outcomes
Doll, K. M., Kalinowski, A. K., Snavely, A. C., Irwin, D. E., Bensen, J. T., Bae-Jump, V. L., Kim, K. H., Le, L. V., Clarke‐Pearson, D. L., & Gehrig, P. A. (2014) · Cancer · doi:10.1002/cncr.29061 · Cited by 29
Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II–IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016)
Harano, K., Terauchi, F., Katsumata, N., Takahashi, F., Yasuda, M., Takakura, S., Takano, M., Yamamoto, Y., & Sugiyama, T. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt527 · Cited by 29
Patient-reported outcomes in ovarian cancer clinical trials
Friedlander, M. L., & King, M. T. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt474 · Cited by 28
Psychometric properties of the Chinese version of the Functional Assessment of Cancer Therapy-Cervix (FACT-Cx) measuring health-related quality of life
Ding, Y. H., Hu, Y., & Hallberg, I. R. (2012) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-10-124 · Cited by 28
Fear of recurrence, emotional well-being and quality of life among long-term advanced ovarian cancer survivors
Osann, K., Wenzel, L. B., McKinney, C. O., Wagner, L. I., Cella, D. F., Fulci, G., Scroggins, M. J., Lankes, H. A., Wang, V., Nephew, K. P., et al. (2023) · Gynecologic Oncology · doi:10.1016/j.ygyno.2023.02.015 · Cited by 28
Self-citation
Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: A phase II trial
Kushner, D. M., Connor, J. P., Sanchez, F. A., Volk, M., Schink, J. C., Bailey, H. H., Harris, L. S., Stewart, S. L., Fine, J. P., & Hartenbach, E. M. (2007) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.12.018 · Cited by 27
Symptom research in gynecologic oncology: A review of available measurement tools
Agarwal, S., & Bodurka, D. C. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2010.07.009 · Cited by 27
A cost–utility analysis of NRG Oncology/Gynecologic Oncology Group Protocol 218: Incorporating prospectively collected quality-of-life scores in an economic model of treatment of ovarian cancer
Cohn, D. E., Barnett, J. C., Wenzel, L. B., Monk, B. J., Burger, R. A., Straughn, J. M., Myers, E. R., & Havrilesky, L. J. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.10.020 · Cited by 29
Non-cancer life stressors contribute to impaired quality of life in ovarian cancer patients
Lutgendorf, S. K., Slavich, G. M., Degeest, K., Goodheart, M. J., Bender, D., Thaker, P. H., Penedo, F. J., Zimmerman, B. M., Lucci, J. A., Méndez, L., et al. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.09.025 · Cited by 25
Symptom management in gynecologic malignancies
Casey, C. G., Chen, L.-M., & Rabow, M. W. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.11.83 · Cited by 25
Effects of the WRITE Symptoms Interventions on Symptoms and Quality of Life Among Patients With Recurrent Ovarian Cancers: An NRG Oncology/GOG Study (GOG-0259)
Donovan, H. S., Sereika, S. M., Wenzel, L. B., Edwards, R. P., Knapp, J. E., Hughes, S. H., Roberge, M. C., Thomas, T. H., Klein, S. J., Spring, M. B., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.00656 · Cited by 23
Supervised and Non-Supervised Exercise Programs for the Management of Cancer-Related Fatigue in Women with Breast Cancer: A Systematic Review and Meta-Analysis
Reverte-Pagola, G., Sánchez-Trigo, H., Saxton, J., & Sañudo, B. (2022) · Cancers · doi:10.3390/cancers14143428 · Cited by 26
Cross‐sectional study of psychosocial well‐being among lesbian, gay, bisexual, and heterosexual gynecologic cancer survivors
Schefter, A., Thomaier, L., Jewett, P., Brown, K., Stenzel, A. E., Blaes, A., Teoh, D., & Vogel, R. I. (2022) · Cancer Reports · doi:10.1002/cnr2.1461 · Cited by 22
Quality of life, symptoms and care needs in patients with persistent or recurrent platinum-resistant ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study
von Gruenigen, V. E., Huang, H. Q., Cella, D. F., Zevon, M. A., Lachance, J. A., Walker, J. L., Salani, R., Modesitt, S. C., Morris, R. T., Bradley, W. H., et al. (2018) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.05.017 · Cited by 22
Self-citation
Patient-reported outcome measures for use in gynaecological oncology: a systematic review
Preston, N. J., Wilson, N., Wood, N. J., Brine, J., Ferreira, J., & Brearley, S. G. (2015) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.13251 · Cited by 22
Targeting those with decreased meaning and peace: a supportive care opportunity
Brown, A. J., Sun, C. C., Urbauer, D. L., Zhukovsky, D. S., Levenback, C., Frumovitz, M., Thaker, P. H., Bodurka, D. C., & Ramondetta, L. M. (2014) · Supportive Care in Cancer · doi:10.1007/s00520-014-2568-6 · Cited by 24
Dyadic coping mediates the effects of attachment on quality of life among couples facing ovarian cancer
Crangle, C. J., Torbit, L. A., Ferguson, S. E., & Hart, T. L. (2019) · Journal of Behavioral Medicine · doi:10.1007/s10865-019-00096-3 · Cited by 23
Health-related quality of life in gynecological oncology: Instruments and psychometric properties
Boling, W., Fouladi, R. T., & Basen-Engquist, K. M. (2003) · International Journal of Gynecological Cancer · doi:10.1046/j.1525-1438.2003.13051.x · Cited by 22
Self-citation
Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial
Pignata, S., Oza, A. M., Hall, G. D., Pardo, B., Mądry, R., Cibula, D., Klát, J., Montes, A., Glasspool, R. M., Colombo, N., et al. (2023) · Gynecologic Oncology · doi:10.1016/j.ygyno.2023.03.019 · Cited by 21
Changes in short-term health-related quality of life in women undergoing gynecologic oncologic laparotomy: an associated factor analysis
Minig, L., Velez, J. I., Trimble, E. L., Biffi, R., Maggioni, A., & Jeffery, D. D. (2012) · Supportive Care in Cancer · doi:10.1007/s00520-012-1571-z · Cited by 21
Feasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: an ANZGOG study
Blinman, P. L., Gainford, M. C., Donoghoe, M. W., Martyn, J. K., Blomfield, P. I., Grant, P., Kichenadasse, G., Vaughan, M. M., Brand, A. H., Shannon, C., et al. (2013) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2013.24.4.359 · Cited by 21
Electronic patient-reported monitoring of symptoms during follow-up of ovarian cancer patients: a feasibility study
Kennedy, F., Shearsmith, L., Holmes, M., Rogers, Z., Carter, R., Hofmann, U., & Velikova, G. (2022) · BMC Cancer · doi:10.1186/s12885-022-09817-5 · Cited by 20
Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum‐resistant ovarian cancer
Hinchcliff, E., Knisely, A. T., Adjei, N. N., Fellman, B. M., Yuan, Y., Patel, A. P., Xu, C., Westin, S. N., Sood, A. K., Soliman, P. T., et al. (2023) · Cancer · doi:10.1002/cncr.35126 · Cited by 20
Self-citation
The FACIT-AI, a new tool for assessing symptoms associated with malignant ascites
Cella, D. F., Neubauer, N. L., Thomas, J., Kutner, J. S., & Seiden, M. V. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.11.013 · Cited by 20
Self-citation
Validation of FACT/GOG-AD subscale for ovarian cancer-related abdominal discomfort: A Gynecologic Oncology Group study
Wenzel, L. B., Huang, H. Q., Cella, D. F., Walker, J. L., & Armstrong, D. K. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.02.011 · Cited by 20
Self-citation
Wanna Get Away? Maintenance Treatments and Chemotherapy Holidays in Gynecologic Cancers
Madariaga, A., Rustin, G. J. S., Buckanovich, R. J., Trent, J. C., & Oza, A. M. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_238755 · Cited by 20
Quality of Life Evaluations of Caregivers of Ovarian Cancer Patients During Chemotherapy Treatment
Le, T. V., Leis, A. M., Pahwa, P., Wright, K., Ali, K., Reeder, B. A., Kinderchuk, M., & Ward, K. (2004) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/s1701-2163(16)30609-0 · Cited by 19
A multicenter, randomized, phase 2 clinical trial to evaluate the efficacy and safety of combination docetaxel and carboplatin and sequential therapy with docetaxel then carboplatin in patients with recurrent platinum‐sensitive ovarian cancer
Secord, A. A., Berchuck, A., Higgins, R. V., Nycum, L. R., Kohler, M. F., Puls, L. E., Holloway, R. W., Lewandowski, G. S., Valea, F. A., & Havrilesky, L. J. (2011) · Cancer · doi:10.1002/cncr.26610 · Cited by 19
Evaluation of the Psychometric Properties of the Functional Assessment of Cancer Therapy-Cervix Questionnaire in Brazil
Fregnani, C. M. S., Fregnani, J. H. T. G., Latorre, M. D. R. D. D. O., & de Almeida, A. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077947 · Cited by 20
Quick-FLIC: validation of a short questionnaire for assessing quality of life of cancer patients
Cheung, Y.-B., Goh, C., Wong, L. C., Ng, G.-Y., Lim, W.-T., Leong, S.-S., Tan, E. H., & Khoo, K. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601782 · Cited by 19
Validation and application of a module of the MD Anderson Symptom Inventory for measuring perioperative symptom burden in patients with gynecologic cancer (the MDASI-PeriOp-GYN)
Wang, X. S., Shi, Q., Williams, L. A., Cleeland, C. S., García-González, A., Chen, T.-Y., Shahid, D. R., Ramirez, P. T., Iniesta, M. D., Siverand, A. M., et al. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.11.004 · Cited by 21
Quality of life assessment during adjuvant and salvage chemotherapy for advance stage epithelial ovarian cancer
Le, T. V., Hopkins, L., & Fung, M. F. K. (2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.03.040 · Cited by 19
Quality-of-Life Issues in the Management of Epithelial Ovarian Cancer
Lowe, T., FERRELL, B. R., & Leong, L. (2007) · Current Treatment Options in Oncology · doi:10.1007/s11864-007-0049-6 · Cited by 20
Validity and reliability of the Greek version of the Quebec Back Pain Disability Scale
Christakou, Α., Andriopoulou, M., & Asimakopoulos, P. (2011) · Journal of Back and Musculoskeletal Rehabilitation · doi:10.3233/bmr-2011-0288 · Cited by 18
Quality of life after early enteral feeding versus standard care for proven or suspected advanced epithelial ovarian cancer: Results from a randomised trial
Baker, J., Janda, M., Graves, N., Bauer, J. D., Banks, M., Garrett, A., Chetty, N., Crandon, A. J., Land, R., Nascimento, M., et al. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.03.048 · Cited by 18
Content validity of the NCCN-FACT Ovarian Symptom Index-18 (NFOSI-18)
Jensen, S. E., Kaiser, K., Lacson, L., Schink, J. C., & Cella, D. F. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.12.002 · Cited by 18
Self-citation
Oral Thalidomide as Palliative Chemotherapy in Women with Advanced Ovarian Cancer
Gordinier, M. E., Dizon, D. S., Weitzen, S. H., DiSilvestro, P., Moore, R. G., & Granai, C. O. (2007) · Journal of Palliative Medicine · doi:10.1089/jpm.2006.0083 · Cited by 17
Intravenous versus oral dexamethasone for prophylaxis of paclitaxel-associated hypersensitivity reaction in patients with primary ovarian, fallopian tube and peritoneal cancer: A double-blind randomized controlled trial
Yanaranop, M., & Chaithongwongwatthana, S. (2016) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.12495 · Cited by 17
The research landscape of the quality of life or psychological impact on gynecological cancer patients: A bibliometric analysis
Zhao, J., Kong, Y., Xiang, Y., & Yang, J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1115852 · Cited by 16
Social support among women who died of ovarian cancer
Jackson, J., Rolnick, S. J., Coughlin, S. S., Neslund-Dudas, C. M., Hornbrook, M. C., Darbinian, J. A., Bachman, D. J., & Herrinton, L. J. (2006) · Supportive Care in Cancer · doi:10.1007/s00520-006-0197-4 · Cited by 15
Lived experiences of women reporting fatigue during PARP inhibitor maintenance treatment for advanced ovarian cancer: a qualitative study
Poort, H., Fenton, A. T. H. R., Thompson, E., Dinardo, M. M., Liu, J. F., Arch, J. J., & Wright, A. A. (2021) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.10.034 · Cited by 15
Disparities in health-related quality of life in women undergoing treatment for advanced ovarian cancer: the role of individual-level and contextual social determinants
Moss, J. L., Murphy, J., Filiaci, V. L., Wenzel, L. B., Minasian, L. M., & Temkin, S. M. (2018) · Supportive Care in Cancer · doi:10.1007/s00520-018-4340-9 · Cited by 15
Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival
Wenzel, L. B., Osann, K., McKinney, C. O., Cella, D. F., Fulci, G., Scroggins, M. J., Lankes, H. A., Wang, V., Nephew, K. P., Maxwell, G. L., et al. (2021) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djab034 · Cited by 15
Self-citation
Assessment of quality of life among advanced ovarian cancer patients in a tertiary care hospital in India
Sarkar, S., Sahoo, P. K., Pal, R., Mistry, T., Mahata, S., Chatterjee, P., Vernekar, M., Mandal, S., Bera, T., & Nasare, V. D. (2022) · Supportive Care in Cancer · doi:10.1007/s00520-021-06735-3 · Cited by 15
Weekly versus tri-weekly paclitaxel with carboplatin for first-line treatment in women with epithelial ovarian cancer
Ngoi, N. Y., Syn, N. L., Goh, R. M., Goh, B. C., Huang, R. Y.-J., Soon, Y. Y., James, E. C., Cook, A. D., Clamp, A. R., & Tan, D. S. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012007.pub2 · Cited by 15
Safety and efficacy of lenalidomide (Revlimid®) in recurrent ovarian and primary peritoneal carcinoma
Zhang, M. M., Chan, J. K., Husain, A., Guo, H. H., & Teng, N. N. H. (2007) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.11.026 · Cited by 15
Quality of life and gynecologic malignancies
Sun, C. C., Frumovitz, M., & Bodurka, D. C. (2005) · Current Oncology Reports · doi:10.1007/s11912-005-0011-3 · Cited by 15
The biology of hope: Inflammatory and neuroendocrine profiles in ovarian cancer patients
Lutgendorf, S. K., Telles, R., Whitney, B. M., Thaker, P. H., Slavich, G. M., Goodheart, M. J., Penedo, F. J., Noble, A. E., Cole, S. W., Sood, A. K., et al. (2023) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2023.12.014 · Cited by 15
Surgical versus medical treatment for ocular surface squamous neoplasia: A quality of life comparison
Mercado, C., Pole, C., Wong, J., Batlle, J. F., Roque, F., Shaikh, N., Murillo, J. C., Galor, A., & Karp, C. L. (2018) · The Ocular Surface · doi:10.1016/j.jtos.2018.09.001 · Cited by 14
Health-Related Quality of Life
Litwin, M. S. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-230-4_13 · Cited by 16
Quality of life assessments in epithelial ovarian cancer patients during and after chemotherapy
Le, T. V., HOPKINS, L., & Fung, M. F. K. (2005) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2005.00141.x · Cited by 14
Patient-Reported Outcomes in Ovarian Cancer: Facilitating and Enhancing the Reporting of Symptoms, Adverse Events, and Subjective Benefit of Treatment in Clinical Trials and Clinical Practice
Campbell, R., King, M. T., Stockler, M. R., Lee, Y. C., Roncolato, F. T., & Friedlander, M. L. (2023) · Patient Related Outcome Measures · doi:10.2147/prom.s297301 · Cited by 13
Health-Related Quality of Life (HRQoL) Assessments in Research on Patients with Adult Rare Solid Cancers: A State-of-the-Art Review
Padilla, C. S., Bergerot, C. D., Dijke, K., Roets, E., Boková, G., Innerhofer, V., Sodergren, S. C., Mancari, R., Bergamini, C., Way, K. M., et al. (2025) · Cancers · doi:10.3390/cancers17030387 · Cited by 13
Management of Ovarian Cancer
Awtrey, C. S. (2012) · JAMA · doi:10.1001/jama.2012.269 · Cited by 13
Pilot randomized trial of an acceptance-based telehealth intervention for women with ovarian cancer and PARP inhibitor-related fatigue
Wright, A. A., Poort, H., Tavormina, A., Schmiege, S. J., Matulonis, U. A., Campos, S. M., Liu, J. F., Slivjak, E. T., Gilmour, A. L., Salinger, J. M., et al. (2023) · Gynecologic Oncology · doi:10.1016/j.ygyno.2023.08.020 · Cited by 12
Bevacizumab Combination Therapy
Dhillon, S. (2012) · Drugs · doi:10.2165/11208940-000000000-00000 · Cited by 12
Patient reported outcomes in evaluation of chemotherapy toxicity in women with gynecologic malignancies: A pilot study
Webster, E., Burke, W. M., Ware, H. M., Jones, B. A., Vattakalam, R. M., Tergas, A. I., Wright, J. D., & Hou, J. Y. (2018) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.07.008 · Cited by 12
Quality of Life of Chinese Patients With Ovarian Malignancies During Chemotherapy Under Condition of No Recurrence
Ding, Y., Zhu, Y., & Zhang, M. (2007) · Cancer Nursing · doi:10.1097/01.ncc.0000270703.57166.e2 · Cited by 12
The challenge of measuring intra-individual change in fatigue during cancer treatment
Moinpour, C. M., Donaldson, G. W., Davis, K. M., Potosky, A. L., Jensen, R. E., Gralow, J. R., Back, A. L., Hwang, J., Yoon, J., Bernard, D. L., et al. (2016) · Quality of Life Research · doi:10.1007/s11136-016-1372-9 · Cited by 12
Self-citation
Quality-of-life concerns in lung cancer patients
Siddiqui, F., Konski, A. A., & Movsas, B. (2010) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/erp.10.81 · Cited by 12
Ovarian cancer study dropouts had worse health‐related quality of life and psychosocial symptoms at baseline and over time
Mercieca‐Bebber, R., Price, M. A., Bell, M. L., King, M. T., Webb, P. M., Butow, P. N., & on behalf of the Australian Ovarian Cancer Study (AOCS) Group (2016) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.12580 · Cited by 11
A practical guide to understanding, using and including patient reported outcomes in clinical trials in ovarian cancer
Wilson, M. K., Mercieca‐Bebber, R., & Friedlander, M. (2018) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2018.29.e81 · Cited by 11
Phase 1 Study of Low-Dose Fractionated Whole Abdominal Radiation Therapy in Combination With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer (GCGS-01)
Ngoi, N. Y. L., Heong, V. Y. M., Tang, J. I.-H., Choo, B. A., Kumarakulasinghe, N. B., Lim, D. G. S., Low, M., Lim, S. E., Lim, Y. W., Leong, Y. H., et al. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.09.059 · Cited by 11
Sintilimab combined with bevacizumab in relapsed/persistent ovarian clear cell carcinoma (INOVA): an investigator-initiated, multicentre clinical trial—a study protocol of clinical trial
Li, R., Liu, X., Song, C., Zhang, W., Liu, J., Jiao, X., Yu, Y., Zeng, S., Chi, J., Zhao, Y., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-058132 · Cited by 11
Estimating health-state utility values for patients with recurrent ovarian cancer using Functional Assessment of Cancer Therapy – General mapping algorithms
Hettle, R., Borrill, J., Suri, G., & Wulff, J. (2015) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s92078 · Cited by 11
Quality of life and treatment response among women with platinum-resistant versus platinum-sensitive ovarian cancer treated for progression: A prospective analysis
Beesley, V. L., Chenevix‐Trench, G., Green, A. C., Wyld, D., O'Rourke, P. K., Wockner, L. F., DeFazio, A., Butow, P. N., Price, M. A., Horwood, K. R., et al. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.10.004 · Cited by 10
A comparison of the FACT-G and the Supportive Care Needs Survey (SCNS) in women with ovarian cancer: unidimensionality of constructs
The Australian Ovarian Cancer Study Group, Colagiuri, B., The Australian Ovarian Cancer Study—Quality of Life Study Investigators, King, M. T., Butow, P. N., McGrane, J. A., Luckett, T., Price, M., & Birney, D. P. (2011) · Quality of Life Research · doi:10.1007/s11136-011-9993-5 · Cited by 10
A Phase II trial of oral capecitabine in patients with platinum – and taxane – refractory ovarian, fallopian tube, or peritoneal cancer
Wolf, J. K., Bodurka, D. C., Verschraegen, C. F., Sun, C. C., Branham, D., Jenkins, A. D., Atkinson, N. E., & Gershenson, D. M. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.12.040 · Cited by 10
Self-citation
Utilization of an Electronic Patient-Reported Outcome Platform to Evaluate the Psychosocial and Quality-of-Life Experience Among a Community Sample of Ovarian Cancer Survivors
Hlubocky, F. J., Daugherty, C. K., Peppercorn, J. M., Young, K., Wroblewski, K., Yamada, S. D., & Lee, N. K. (2022) · JCO Clinical Cancer Informatics · doi:10.1200/cci.22.00035 · Cited by 9
Exercise during CHemotherapy for Ovarian cancer (ECHO) trial: design and implementation of a randomised controlled trial
Hayes, S. C., Obermair, A., Mileshkin, L., Davis, A. J., Gordon, L. G., Eakin, E., Janda, M., Beesley, V. L., Barnes, E. H., Spence, R. R., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-067925 · Cited by 9
Effect of method of administration on longitudinal assessment of quality of life in gynecologic cancer: an exploratory study.
Gil, K. M., Frasure, H. E., Hopkins, M. P., Jenison, E. L., & von Gruenigen, V. E. (2005) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-3-6 · Cited by 9
Development and validation of the measure of ovarian symptoms and treatment concerns for surveillance (MOST-S26): An instrument to complement the clinical follow-up of women with ovarian cancer after completion of first-line treatment
Campbell, R., King, M. T., Ross, T. L., Cohen, P. A., Friedlander, M. L., & Webb, P. M. (2021) · Gynecologic Oncology · doi:10.1016/j.ygyno.2021.08.022 · Cited by 9
Acceptability and Feasibility of Early Palliative Care Among Women with Advanced Epithelial Ovarian Cancer: A Randomized Controlled Pilot Study
Cusimano, M. C., Sajewycz, K., Harle, I. A., Giroux, J., Hanna, T., Willing, S., Martin, V., & Francis, J. (2021) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/j.jogc.2021.03.005 · Cited by 8
Quality of Life in Ovarian Cancer Treatment and Survivorship
Gonçalves, V. (2013) · InTech eBooks · doi:10.5772/54542 · Cited by 8
Health-related quality of life outcomes of docetaxel/carboplatin combination therapy vs. sequential therapy with docetaxel then carboplatin in patients with relapsed, platinum-sensitive ovarian cancer: Results from a randomized clinical trial
Pokrzywinski, R. M., Secord, A. A., Havrilesky, L. J., Puls, L. E., Holloway, R. W., Lewandowski, G. S., Higgins, R. V., Nycum, L. R., Kohler, M. F., & Revicki, D. A. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.08.015 · Cited by 8
Phase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced Ovarian/Tubal/Peritoneal Cancer: A Gynecologic Oncology Group 0212:NRG Oncology Study
Copeland, L. J., Brady, M. F., Burger, R. A., Rodgers, W. H., Huang, H. Q., Cella, D. F., O’Malley, D. M., Street, D. G., Tewari, K. S., Bender, D., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00146 · Cited by 8
Self-citation
Psychometrics of patient-reported bother from side effects of treatment single-items in industry-sponsored oncology trials
Trask, P. C., Holt, T., & Pearman, T. P. (2023) · Quality of Life Research · doi:10.1007/s11136-023-03426-w · Cited by 8
Weekly dose-dense paclitaxel and carboplatin in recurrent ovarian carcinoma: A phase II trial
Shawky, H., Tawfik, H. A., & Hewidy, M. (2014) · Journal of the Egyptian National Cancer Institute · doi:10.1016/j.jnci.2014.05.001 · Cited by 8
Health-related quality of life in women with recurrent ovarian cancer receiving paclitaxel plus trebananib or placebo (TRINOVA-1)
Fujiwara, K., Monk, B. J., Lhommé, C., Coleman, R. L., Brize, A., Oaknin, A., Ray-Coquard, I., Fabbro, M., Provencher, D. M., Bamias, A., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw147 · Cited by 8
Treatment of recurrent or persistent platinum-refractory ovarian, fallopian tube or primary peritoneal cancer with gemcitabine and topotecan
Goff, B. A., Holmberg, L., Veljovich, D. S., & Kurland, B. F. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.04.037 · Cited by 8
Patient-Reported Outcomes
Carey, M. S., & Gotay, C. C. (2011) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e31821bb8be · Cited by 7
First-line PARP inhibitor maintenance treatment in ovarian carcinoma for older adult women: a review of the current literature
Hernandez, M. M., Costa, S. C., Coloma, C. S., Cutillas, A. Q., Barretina-Ginesta, M.-P., & Sanchís, A. C. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03609-y · Cited by 7
Development of a Postsurgical Patient-Reported Outcome Instrument for Women With Vulvar Neoplasia
Senn, B., Mueller, M. D., Hasenburg, A., Blankenstein, T. J. F., Kammermann, B., Hartmann, A., Donovan, H. S., Eicher, M., Spirig, R., & Engberg, S. J. (2012) · Oncology nursing forum · doi:10.1188/12.onf.e489-e498 · Cited by 7
Chronic difficulties are associated with poorer psychosocial functioning in the first year post‐diagnosis in epithelial ovarian cancer patients
Garvin, L. A., Slavich, G. M., Schrepf, A., Davis, L. Z., Thaker, P. H., Goodheart, M. J., Cole, S. W., Sood, A. K., & Lutgendorf, S. K. (2021) · Psycho-Oncology · doi:10.1002/pon.5682 · Cited by 7
Challenges and opportunities to address the emerging burden of targeted therapies in ovarian cancer
Abdul-Aziz, S., Bhattarai, N., Vale, L. D., Sagoo, G. S., & Mukhopadhyay, A. (2025) · Gynecologic Oncology Reports · doi:10.1016/j.gore.2025.101680 · Cited by 6
Analysis of risk factors for negative emotions in perioperative period of ovarian cancer patients and their impact on prognosis
He, J., & Zhang, Y. (2023) · Gland Surgery · doi:10.21037/gs-23-94 · Cited by 6
Weekly combination of topotecan and gemcitabine in early recurrent ovarian cancer patients: A French multicenter phase II study
Joly, F., Petit, T., Pautier, P., Guardiola, E., Mayer, F., Chevalier-Place, A., Delva, R., Sevin, E., Henry-Amar, M., & Bourgeois, H. P. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.08.024 · Cited by 6
Rationale and study protocol for the Patient-Centered Outcome Aid (PCOA) randomized controlled trial: A personalized decision tool for newly diagnosed ovarian cancer patients
Wenzel, L. B., Mukamel, D. B., Osann, K., Havrilesky, L. J., Sparks, L., Lipscomb, J., Wright, A., Walker, J. L., Alvarez, R. D., Le, L. V., et al. (2017) · Contemporary Clinical Trials · doi:10.1016/j.cct.2017.03.006 · Cited by 6
Use and Interpretation of the National Comprehensive Cancer Network- Functional Assessment of Cancer Therapy Symptom Indexes in Palliative Research and Treatment: Special Considerations in Ovarian Cancer
Jensen, S. E. (2013) · Journal of Palliative Care & Medicine · doi:10.4172/2165-7386.1000145 · Cited by 6
Reliability, Validity and Important Difference Estimates for the NCCN-FACT Ovarian Symptom Index-18 (NFOSI-18)
Trigg, A., Tabata‐Kelly, M., Iadeluca, L. L., Chang, J., Moreno‐Koehler, A., Yaworsky, A., Krohe, M., Rider, A., Cappelleri, J. C., Cella, D. F., et al. (2021) · Future Oncology · doi:10.2217/fon-2021-0358 · Cited by 5
Self-citation
Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer
Campbell, R., Costa, D. S. J., Stockler, M. R., Lee, Y. C., Ledermann, J. A., Berton, D., Sehouli, J., Roncolato, F. T., Connell, R. O., Okamoto, A., et al. (2022) · Gynecologic Oncology · doi:10.1016/j.ygyno.2022.05.024 · Cited by 5
What's in it for me?: A value assessment of gynecologic cancer clinical trials for Black women
Oluloro, A., Temkin, S. M., Jackson, J., Swisher, E. M., Sage, L., & Doll, K. M. (2023) · Gynecologic Oncology · doi:10.1016/j.ygyno.2023.03.002 · Cited by 5
Development of the Berlin Symptom Checklist Ovary (BSCL-O) for the measurement of quality of life of patients with primary and recurrent ovarian cancer: results of a phase I and II study
on behalf of the Nord-Ostdeutschen Gesellschaft für Gynäkologische Onkologie (NOGGO) working group “Quality of life”, Koensgen, D., Oskay-Oezcelik, G., Katsares, I., Walle, U., Klapp, C., Mustea, A., Stengel, D., Porzsolt, F., Lichtenegger, W., et al. (2009) · Supportive Care in Cancer · doi:10.1007/s00520-009-0733-0 · Cited by 5
Validation of the Mexican-Spanish Version of the EORTC QLQ-OV28 Instrument for the Assessment of Quality of Life in Women with Ovarian Cancer
Gallardo‐Rincón, D., Toledo‐Leyva, A., Bahena-González, A., Montes-Servín, E., Munoz-Moñtano, W., Coronel-Martínez, J. A., & Oñate-Ocaña, L. F. (2020) · Archives of Medical Research · doi:10.1016/j.arcmed.2020.07.004 · Cited by 5

Authors: Basen-Engquist, K., Bodurka-Bevers, D., Fitzgerald, M. A., Webster, K., Cella, D., Hu, S., & Gershenson, D. M.
Affiliations: Northwestern University (US)
From the University of Texas M.D. Anderson Cancer Center, Houston, TX; and Center on Outcomes, Research and Education, Evanston Northwestern Healthcare and Northwestern University, Evanston, IL.
ORCID: Basen-Engquist, Karen
Webster, Kimberly
Cella, David
Hu, Shaohua
Gershenson, David M.
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2001-03-15
Volume: 19
Issue: 6
Pages: 1809-1817
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2001.19.6.1809
OpenAlex: W2244770355
Cited by: 280
References: 28
Citations by year: 2026: 6 · 2025: 3 · 2024: 10 · 2023: 17 · 2022: 31 · 2021: 17 · 2020: 4 · 2019: 10 · 2018: 10 · 2017: 10 · 2016: 11 · 2015: 11 · 2014: 16 · 2013: 16 · 2012: 14
FWCI: 2.18
Type: journal article
Language: en
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer survivorship and care
Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Childhood Cancer Survivors' Quality of Life
Keywords: ovarian cancer, quality of life, test-retest reliability, internal consistency, performance status, sensitivity to change, emotional well-being, functional status, instrument validation
MeSH terms: Activities of Daily Living, Adult, Aged, Clinical Trials as Topic, Emotions, Family Health, Female, Health Status, Humans, Middle Aged, Neoplasm Staging, Ovarian Neoplasms, Quality of Life, Surveys and Questionnaires, Sensitivity and Specificity, Social Support, Reproducibility of Results, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Reliability and validity of the functional assessment of cancer therapy-ovarian

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks